- CXCL3 is a potential target for breast cancer metastasis.
CXCL3 is a potential target for breast cancer metastasis.
Current cancer drug targets (2014-03-13)
Amanda Lay Pin See, Poh Kuan Chong, Ssu-Yi Lu, Yoon Pin Lim
PMID24605943
RESUMEN
Secreted proteins are an attractive minefield for cancer drug targets. An iTRAQ-based tandem mass spectrometry approach was employed to relatively quantify proteins in the secretomes of four isogenic breast cancer cell lines with increasing metastatic potential. CXCL3 was found to be upregulated in aggressive cancer cells. SiRNA and antibody neutralization studies supported a role of CXCL3 in metastatic processes. Meta-analysis of the mRNA level of CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer. Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
MATERIALES
Referencia del producto
Marca
Descripción del producto
Sigma-Aldrich
Fosfato de potasio monobasic, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
Fosfato de potasio monobasic, buffer substance, anhydrous, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.5-100.5%
Sigma-Aldrich
Fosfato de potasio monobasic, meets analytical specification of Ph. Eur., NF, E340, anhydrous, 98-100.5% (calc. to the dried substance)
Sigma-Aldrich
Fosfato de potasio monobasic, BioUltra, for molecular biology, anhydrous, ≥99.5% (T)
Supelco
Fosfato de potasio monobasic, Pharmaceutical Secondary Standard; Certified Reference Material